Barrett’s Esophagus Panel: Establishing Individual Patient Risk for Progression to Esophageal Cancer
Understand how TissueCypher® predicts future development of HGD/EAC in patients with BE. Impacts patient-care decisions as demonstrated by case studies.
TissueCypher® Objectively Risk Stratifies Barrett’s Esophagus Patients with Low-Grade Dysplasia*
Pathologic diagnosis is highly variable, even among experts, while TissueCypher® provides objective risk stratification. TissueCypher outperformed community and expert pathologists for sensitivity and detected >50% of NDBE progressors who were down-staged (i.e. missed).
Prediction of Progression in Barrett’s Esophagus Using a Tissue Systems Pathology Test: A Pooled Analysis of International Multicenter Studies*
Addition of TissueCypher® significantly increases the accuracy and power of risk prediction providing for personalized management of BE patients.
Risk Stratification and Management of Dysplastic Barrett’s Esophagus*
Risk stratification is important in managing BE patients and biomarker assays such as TissueCypher® are “ready for Prime Time” in identifying patients at high risk for progression.
* All content is derived from presentations and similar offerings made at Digestive Disease Week® 2021 and is presented with permission of DDW, LLC.
Barrett’s Esophagus Panel: Predicting Progression in Barrett’s Esophagus Recent Advances Webinar
A panel discussion on the clinical challenges associated with predicting progression to esophageal adenocarcinoma in patients with Barrett’s esophagus.
